Figure 1. A) PRISMA flow diagram of study selection process
Figure 2. Risk of bias graph. A) Risk of bias summary B) Risk for each included study.
Figure 3. Forest Plots of the effect of Roxadustat on cardiovascular-related events. A) Forest Plots of the effect of Roxadustat on cardiovascular-related events based on NDD or DD patients. B) Forest Plots of the effect of Roxadustat on cardiovascular-related events compared with placebo or ESA. All outcomes are reported in risk ratios (RRs) for treatment vs the comparator and 95% credible intervals (95%-CI).
Figure 4. Forest Plots of the effect of Roxadustat on renal adverse events A) Forest Plots of the effect of Roxadustat on renal adverse events based on NDD or DD patients. B) Forest Plots of the effect of Roxadustat on renal adverse events compared with placebo or ESA. All outcomes are reported in risk ratios (RRs) for treatment vs the comparator and 95% credible intervals (95%-CI).
Figure 5. Forest Plots of the effect of Roxadustat on ESKD A) Forest Plots of the effect of Roxadustat on ESKD based on NDD or DD patients. B) Forest Plots of the effect of Roxadustat on ESKD compared with placebo or ESA. All outcomes are reported in risk ratios (RRs) for treatment vs the comparator and 95% credible intervals (95%-CI).
Figure 6. Forest Plots of the effect of Roxadustat on hyperkalemia A) Forest Plots of the effect of Roxadustat on hyperkalemia based on NDD or DD patients. B) Forest Plots of the effect of Roxadustat on hyperkalemia compared with placebo or ESA. All outcomes are reported in risk ratios (RRs) for treatment vs the comparator and 95% credible intervals (95%-CI).
Figure 7. Forest Plots of the effect of Roxadustat on hypertension A) Forest Plots of the effect of Roxadustat on hypertension based on NDD or DD patients. B) Forest Plots of the effect of Roxadustat on hypertension compared with placebo or ESA. All outcomes are reported in risk ratios (RRs) for treatment vs the comparator and 95% credible intervals (95%-CI).